癌症认识史

肿瘤是人类自己细胞的扭曲变体,这意味着我们不能完全摆脱癌症。美国医生悉达多·穆克吉曾经在波士顿为一位腹部癌症患者进行治疗,这位病人曾接受化疗,但又复发了,不得不再次接受治疗。病人说,"我愿意继续治疗,但是,我必须知道我在对抗的敌人是什么"。从某种意义上来说,穆克吉历时6年完成的《众病之王》一书,就是通过回溯这一疾病的起源,讲述它4000年的历史发展,来试图回答这位患者的问题。在撰写癌症"历史"的过程中。穆克吉感到,他所撰写的不是某个"物",而是某个     

单克隆抗体连接表阿霉素导向治疗乳腺癌的体外基础研究

本文报道了抗人乳腺癌单克隆抗体Ｍ４Ｇ３与表阿霉素结合物的制备及其体外免疫活性．首先用高碘酸钠氧化葡聚糖，使其成为多醛基葡聚糖，并以此为中间载体将表阿霉素与单抗连接，经测定，每一抗体分子能携带３１个药物分子，且结合物仍具有良好的免疫活性，为单抗导向药物治疗乳腺癌提供了理论基础和实验依据．     

女性乳腺癌危险因素的Logistic回归分析

女性乳腺癌危险因素的研究资料采集于广州，韶关，肇庆等地８间大医院。按１：２配对设计，总共收集了１２５个病例一对照组作回顾性调查。经条件Ｌｏｇｉｓｔｉｃ回归分析得：保护因子有喝茶习惯，ＯＲ＝０．３９１３；危险因子有精神创伤，ＯＲ＝３．４３３８；乳腺炎史，ＯＲ＝３．４０９９；被动吸烟，ＯＲ＝２．０７９６；平均摄油量，ＯＲ＝３．１７７３；流产，ＯＲ＝１．３５４４；癌症家族史，ＯＲ＝５．６７９７。     

PKCα反义RNA对乳腺癌细胞增殖及cyclinD1和CDK4表达的影响

ＰＫＣ,ｃｙｃｌｉｎ和ＣＤＫ基因直接参于调控细胞的增殖与分化,因此它们在细胞癌变中的作用已成为重要的研究课题。利用反义ＲＮＡ技术抑制ＰＫＣａ基因的表达,然后观察分析了乳腺癌细胞增殖的变化以及对ｃｙｃｌｉｎＤ１和ＣＤＫ４基因表达的影响。     

Role of FGF-2／FGFR signaling pathway in cancer and its signification in breast cancer

Fibroblast growth factor-2 (FGF-2) is a member of a large family of proteins that bind heparin and heparan sulfate and modulate the function of a wide range of cell types. It has been proved that FGF-2 stimulates the growth and development of new blood vessels (angiogenesis) that contribute to the pathogenesis of several diseases (i.e. cancer, atherosclerosis). However, many of the biological activities of FGF-2 have been found to depend on its receptor抯 intrinsic tyrosine kinase activity and second messengers such as the mitogen activated protein kinases. This review will focus on the mechanism of FGF-2/FGFR induced signaling pathway in tumor and human breast cancer.     

复发转移乳腺癌68例临床分析

：目的探讨复发转移乳腺癌的临床特点、最佳治疗方法和治疗效果。方法对68例复发转移乳腺癌病人，采取化疗，结合手术、放射治疗、术后辅助化疗。结果46例伴有内脏转移的多个部位以上复发转移病人，经化疗病灶缩小明显（PR）14例，病情稳定（SO）16例，病情进展（PD）16例，临床获益（CR＋PR＋SD）65％（30/46），1年生存率65％。22例单个复发转移病灶化疗后PR20例，PD2例，临床获益90％（20/22），2年无瘤生存率90％。结论乳腺癌复发转移应以化疗为主，配合手术、放疗、及内分泌治疗，可提高患者生存期，改善生活质量。     

Dialdehyde starch nanoparticles： Preparation and application in drub carrier

Dialdehyde starch nanoparticles (DASNP) were prepared by the redox reaction of NaIO4 and starch in water-in-oil microemulsion. IR spectrum showed that DASNP had aldehyde groups, and quantitative alkali consumption showed that its dialdehyde content was about (50±5)%. The average diameter of DASNP determined by SEM was about 100 nm. TGA-DTA showed that its thermal stability was better than starch nanoparticle (StNP) and dialdehyde starch (DAS). Its low biological toxicity was detected by cell experiment. Also the best mass ratio of doxorubicin (DOX) to combined DASNP detected by UV-VIS was 15 : 1, and the product was effective for controlled release of DOX. The cell experiment showed that the drug-carrier particle (DOX-DASNP) can release DOX for a long time and strengthened the effect of the anticancer drug. This work demonstrates that the DASNP, which has good thermal stability, small particle size, low biological toxicity, and slowly anticancer drug-releasing to strengthen drug effect, is a potentially useful carrier for anticancer drug.     

VEGF 和 PCNA在乳腺癌组织中表达的意义

为了探讨血管内皮生长因子（VEGF）和增殖细胞核抗原（PCNA）在乳腺癌组织中的表达及其与病理学分级关系，采用免疫组织化学SP法检测102例乳腺癌及其中48例癌旁正常乳腺组织中VEGF和PCNA的表达，实验结果显示VEGF在乳腺癌组织中的阳性表达率为84．31％，癌乳腺组织中则为12．50％，两者间具有高度显著性差异（P＜0．01），PCNA在乳腺癌组织中的阳性表达率为78．43％，癌旁正常乳腺组织中则为8．33％，它们之间的差异有高度显著性（P＜0．01），VEGF和PCNA的阳性表达率与乳腺癌病理学分级呈正相关，说明VEGF和PCNA阳性表达作为乳腺 辅助诊断指标。